News Hub | News Direct

News Release

1606 Corp secures $20 million in financing as it looks to grow through acquisition

1606 Corp.

1606 Corp CEO Greg Lambrecht joined Steve Darling from Proactive to share news about the CBD company that is looking for major growth this year through several avenues including acquisitions. To help in that, the company has just announced an equity financing agreement with GHS Investments for up to $20 million. Lambrecht told Proactive more about how he sees the CBD industry as a whole and also the company’s strategy when it comes to acquisitions as it looks to the future and a possible listing on the Nasdaq. Contact Details Proactive Canada +1 604-688-8158 na-editorial@proactiveinvestors.com

February 24, 2023 08:06 AM Eastern Standard Time

Video

News Release

Eloxx Pharmaceuticals making progress on Phase 2 clinical study for ELX-02 Alport syndrome candidate

Eloxx Pharmaceuticals

Eloxx Pharmaceuticals president and CEO Sumit Aggarwal joins Proactive's Natalie Stoberman to discuss the latest update on the clinical study for its lead investigational product candidate ELX-02. Aggarwal said the first batch of patients has now been enrolled in its Phase 2 study of ELX-02 for the treatment of Alport syndrome in patients with nonsense mutations. Up to eight Alport syndrome patients with nonsense mutations in the COL4 gene will be dosed for two months with a three-month follow-up. With this timeline, the company is expected to remain on track to deliver topline clinical results from this trial in the first half of 2023. Contact Details Proactive US +1 347-449-0879 na-editorial@proactiveinvestors.com

February 24, 2023 08:01 AM Eastern Standard Time

Video

Dry Eye Disease Impacts 49 Million Americans And Disproportionately Affects Women, But Current Treatments Aren't Fully Effective – OKYO Pharma's Drug Candidate Could Be The Solution

OKYO Pharma

By David Willey, Benzinga An eye condition that has been described as a common disease currently affects as many as 49 million Americans. Dry Eye Disease (DED) afflicts over 15% of Americans over 50 and disproportionately affects women and DED patients are not well served by currently approved drugs. It’s concerning facts like these that inspired the biopharmaceutical company OKYO Pharma Ltd. (NASDAQ: OKYO) to develop a drug that can help the millions suffering from DED. DED, a condition often associated with aging, is caused when a tear film dysfunction means tears are unable to provide adequate lubrication for the eyes. Symptoms include a scratchy sensation in the eyes, light sensitivity, blurry vision, and eyesight fatigue. DED can also cause ocular pain from damage to the surface of the eye, and the market surrounding DED treatment is currently worth over $5 billion. DED incidence in the US has been increasing, and there are also extrinsic factors that could be behind the increasing rate of DED in America. As the population ages, the number of people most at risk for DED increases, and lifestyle choices like contact lenses and heavy blue light exposure contribute to dry eyes and eventual ocular damage. DED is a chronic condition, meaning treatments need to be suitable for long-term use, but the drugs currently available on the market don’t appear to be filling this need. Some like Eysuvis have seen success but are strictly a short-term treatment, while others, including Restasis, Xiidra, and Cequa, have discomforting side effects which lead large numbers of patients to not refill their prescriptions. Now, OKYO Pharma is looking to bring real solutions to people suffering from DED through the novel drug it is currently developing, OK-101, which is administered topically as eye drops. The drug’s anti-inflammatory activity treats DED while pain-reducing activity alleviates DED-associated ocular pain. Solving Inflammation And Ocular Pain OKYO Pharma is a London-based drug development company that is looking to bring a new drug to the market. Though drug development is a notoriously slow process, OKYO’s novel OK-101 treatment is seeing rapid development that may get it to market in record time. The team is led by Dr. Gary Jacob, CEO of OKYO Pharma and director of the drug’s development. Dr. Jacob is a drug development veteran with a proven record, as he has already developed and brought to market two Federal Drug Administration (FDA)-approved drugs. Also on the team is Dr. Raj Patil, Chief Scientific Officer who has expertise and years of experience in ophthalmology drug development. Focus is often what separates success from failure in the biotech space, with companies failing when they try to cast their net too wide. On the other hand, OKYO Pharma is laser-focused on the development of its drug OK-101 for DED treatment, and it will be collecting data from its clinical trials that are starting soon. In fact, OKYO received FDA approval to skip its phase one trial and jump straight to its phase two efficacy trials, with the possibility of an accelerated regulatory submission. Pre-clinical animal data indicate that OK-101 reduces both inflammation of the eye and the corneal neuropathic pain which results from nerve damage to the eye caused by DED. There currently isn’t a topical treatment for ocular pain approved by the FDA, which is another reason OKYO Pharma is excited to move ahead with the trials for OK-101. Similar companies in the market include Aldeyra Therapeutics (NASDAQ: ALDX) and Tarsus Pharmaceuticals (NASDAQ: TARS), both of which have a market cap of around $400 million. Want to learn more about what OKYO Pharma is doing to tackle DED and other eye diseases? Visit its website. This article was originally published on Benzinga here. OKYO Pharma Limited (LSE: OKYO; NASDAQ: OKYO) is a life sciences company admitted to listing on NASDAQ and on the standard segment of the Official List of the UK Financial Conduct Authority and to trading on the main market for listed securities of London Stock Exchange plc. OKYO is focusing on the discovery and development of novel molecules to treat inflammatory dry eye diseases and chronic pain. Certain statements made in this announcement are forward-looking statements. These forward-looking statements are not historical facts but rather are based on the Company’s current expectations, estimates, and projections about its industry; its beliefs; and assumptions. Words such as ‘anticipates,’ ‘expects,’ ‘intends,’ ‘plans,’ ‘believes,’ ‘seeks,’ ‘estimates,’ and similar expressions are intended to identify forward-looking statements. These statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties, and other factors, some of which are beyond the Company’s control, are difficult to predict, and could cause actual results to differ materially from those expressed or forecasted in the forward-looking statements. The Company cautions security holders and prospective security holders not to place undue reliance on these forward-looking statements, which reflect the view of the Company only as of the date of this announcement. The forward-looking statements made in this announcement relate only to events as of the date on which the statements are made. The Company will not undertake any obligation to release publicly any revisions or updates to these forward-looking statements to reflect events, circumstances, or unanticipated events occurring after the date of this announcement except as required by law or by any appropriate regulatory authority. This post contains sponsored advertising content. This content is for informational purposes only and is not intended to be investing advice. Contact Details Christine Petraglia - TraDigital IR christine@tradigitalir.com Company Website https://okyopharma.com/

February 23, 2023 10:30 AM Eastern Standard Time

74 Million Americans Don’t Have Dental Insurance—Dental Savings Plans Are the Low-Cost Alternative That’s Making It Possible to Get Oral Care Anyway

DentalPlans.com

By Rachael Green, Benzinga A 2022 study in the Journal of Public Health Dentistry reviewed the 2019 data of 4.67 million Medicaid recipients and found that those who received at least five continuous years of preventative dental care were spending 43% less on dental care than those who’d received no preventative care at all. Those savings were in part because they were much less likely to need oral surgery or emergency care for severe pain caused by decay or oral disease. Yet four out of ten Americans delay seeing the dentist, even when they have a toothache or other problem they know should be addressed. The reason? Dental care can be expensive and millions of Americans don’t have dental insurance. But there is some good news. More and more Americans are turning to dental savings plans as an alternative to or supplement for insurance. Here’s how they work and what discounts they provide plan members. How Do Dental Savings Plans Work? When someone joins a dental savings plan, they pay an annual membership fee upfront to join — plans start as low as $80 but typically hover somewhere around $150 per year for an individual. Then, they can go to any participating dentist, show their membership card and they’ll be charged the special discounted rate available on the majority of procedures, every time they go. To choose a plan, they can use a marketplace like DentalPlans.com to shop around and compare plans, similar to the way you’d compare insurance. Choosing the best fit comes down to finding a plan that is accepted by a dentist near you and that includes discounts for the procedures you need. Discounts Can Be Substantial Plans vary but procedures are usually discounted by 10% to 60%. A routine checkup that might normally cost $73 per person, for example, can be reduced to as little as $19 per person, making it much easier to keep up with essential preventative care. Major work like full dentures or dental implants that might normally be prohibitively expensive can be discounted significantly. Discounts Kick In Right Away With insurance, coverage for certain procedures might not kick in for months or even a full year. That means a person with no insurance who finds out they need urgent work done like a root canal or tooth extraction won’t be able to use their benefits, even though they’re paying the premium until that waiting period is over. While Insurance has waiting periods, Dental savings plans do not. Individuals can join any time of year and the discounts kick in as soon as their membership is activated, a process that typically takes about 1-3 business days. There Are No Annual Limits Most dental insurance coverage caps out at $1,000-$2,000 and even the most generous plans cap out at $5,000. Once your dental care for the year hits that annual maximum, your insurance won’t pay for anything else—even if it’s a procedure your plan would normally cover. This means even insured patients have to make tough decisions about whether to delay needed treatments until their maximum resets or skip it altogether in the case of a procedure that costs more than the annual maximum on its own. With a dental savings plan, plan members don’t have that problem. No matter how much or what kind of work they need, they’ll always pay the discounted rate on virtually any procedure. There Are No Exclusions Or Tricky Care Exceptions Because a discount program isn’t the same as insurance, plan members don’t have to worry about being excluded from certain care on the basis of current health conditions. They also don’t have to go through the stress of determining whether a procedure is medically necessary or qualifies for coverage. Better yet, many plans also include steep discounts on cosmetic work like veneers or teeth whitening that many insurers won’t cover at all. So long as the procedure is listed in the savings plan and you go to a participating dentist, you can get the dental care you need at the discounted rate provided in the plan. While no two dental savings plans are the same and they don’t all include the same procedures or dentists, they’re extremely straightforward and it’s easy to understand what you’re getting before you sign up. On DentalPlans.com, for example, you can filter by the procedure as well as location or dentist. This makes it easy to find a program that includes the dental care you actually need. To learn more visit DentalPlans.com This article was originally published on Benzinga here. DentalPlans.com, founded in 1999, is a leading online marketplace for dental savings plans in the U.S., helping more than a million people to affordably access quality healthcare services. Our mission is to empower consumers with the tools, information, and services that they need to live happier, healthier lives. Discount Health Program consumer & provider surveys indicate average savings of 50%. Savings may vary by provider, location, and plan. This post contains sponsored advertising content. This content is for informational purposes only and is not intended to be investing advice. Contact Details Matthew Wong matthew.wong@wpromote.com Company Website https://www.dentalplans.com/

February 23, 2023 09:25 AM Eastern Standard Time

Clear Vision Impact Fund Announces Latest Round of Investments

Siebert Williams Shank

Since its final closing in March 2022, the Clear Vision Impact Fund (Clear Vision or CVIF) has provided loans to minority-owned businesses across the U.S. It has originated loans to seven portfolio companies, including two new investments that closed last month. "The Clear Vision team embraces the opportunity to provide liquidity and growth capital to small and mid-sized businesses that serve communities in a manner that is consistent with our impact mission," said Christopher J. Williams, principal of Clear Vision’s general partner and Chairman of Siebert Williams Shank & Co., LLC. "We are energized that our portfolio companies, which span a range of industries, strive to save jobs and increase job training among underserved communities." "The CVIF loan played a critical role in P&THE Manufacturing Acquisition’s first acquisition of Ross Aluminum. We had to work expeditiously in closing the deal, condensing a timeline that would normally take four to five months down to six to eight weeks at the behest of the previous owner,” said Pancho Hall, CEO and Chairman of P&THE Manufacturing. “Thanks to the professionalism, accuracy, and pure determination of all responsible parties, we were able to finalize the loan and close on this amazing opportunity, which positions us to capitalize on our strategy to gain a collection of world-class enterprises that serve global communities as their minority-business enterprise of choice." “The asset management business needs a big funnel to find innovative solutions that impact the broader society,” said Dabo Horsfall, Founder and CEO of Tensile Investments. “CVIF has been a true growth partner; their approach to investing is fair, their feedback is constructive, and their approach to partnership is genuine. CVIF has supported Tensile’s mission to provide clean mobility solutions that improve the lives of ALL people while developing electric vehicle charging infrastructure in a profitable manner.” “Valeo Networks teamed with the Clear Vision Impact Fund in October 2021 for the purpose of growth through acquisition. As our financing partner, Clear Vision has fueled our acquisition growth, allowing us to double in size by funding three acquisitions in our first year of partnership, making Valeo Networks one of the 50 largest Managed Security Service Providers (MSSPs) in the United States,” said Travis Mack, CEO and Chairman of Valeo Networks. “Clear Vision has been very flexible and worked closely with Valeo to gain a detailed understanding of our business model and acquisition strategy, which helps us to be nimble and efficient during acquisition. We look forward to continuing to work with Clear Vision and continuing our growth to more than $50 million annual revenue over the next 2-4 years to become one of the 10 largest MSSPs nationwide.” “The Clear Vision Impact Fund partnered with Medi-Fare in the immediate aftermath of the COVID-19 pandemic. Whether it is collaborating on enhancing our business through new client targets, crafting impact strategies to increase local hiring, or producing marketing materials, the Clear Vision team has never viewed a task as too small. We look forward to its continued support in 2023 as Medi-Fare scales its production capacity,” said Artis Terrell Jr., CEO of Medi-Fare Drug Pharmaceutical Compounding. “At CVIF, we have been fortunate in continuing to source unique opportunities to support diverse entrepreneurs and investors that not only share our passion for positively impacting underserved communities, but also demonstrate that impact and financial performance are not mutually exclusive,” said Kyle C. Sligar, Chief Credit Officer and Portfolio Manager of the Clear Vision Impact Fund. We look forward to deploying more customized debt solutions for both existing portfolio companies and new prospects as they execute on their growth initiatives.” In addition to providing financing, Clear Vision aims to support portfolio companies by working with them to define and execute on their impact goals, evaluating proposed operational improvements and strategic initiatives, and introducing them to prospective customers and partners, among other things. To date, Clear Vision has provided loans to seven African American-owned businesses, several of which are detailed below. P&THE Manufacturing, headquartered in metro Detroit, is a minority-owned holding company comprised of businesses that provide manufacturing solutions. It differentiates itself in the marketplace as a true owner operator who has experience working in and managing businesses at the senior level ranging from the lower middle market to Fortune 100 companies. Learn more at www.rossal.com. Tensile Investments is an impact driven holding company that provides clean mobility options in transit deserts. It develops smart mobility hubs and funds clean first-last mile transportation. Tensile Investments partners with municipalities and private property owners to create smart mobility hubs by modernizing parking lots and garages to provide electric vehicle (“EV”) fleet parking and charging, electric micro-transit services, clean distributed energy services, public EV charging, and electric micro-mobility services. Learn more at www.tensileinvestments.com. Medi-Fare Drug Pharmaceutical Compounding is a minority-owned 503B pharmaceutical compounding facility registered with the Federal Drug Administration as an Outsourcing Facility. Medi-Fare serves as a partner to hospitals and other healthcare providers to supply much needed medications to help improve positive outcomes for their patients and fulfill the need for the ever-growing number of medicines in shortage or backorder situations. Headquartered in Blacksburg, South Carolina, it serves a range of medical facilities and acts as a health care partner for hospital systems, surgery centers, clinics, and doctor’s offices. Learn more at www.medifaredrug.com. Valeo Networks is a full-service, award-winning Managed Security Service Provider (MSSP) that serves state, county, and municipal markets; small-to-medium businesses; and non-profit organizations. Firmly seated in the top 5% of revenue generating MSSPs nationwide—making it one of the largest MSSPs nationally—Valeo Networks provides solutions in the areas of cybersecurity, compliance, cloud, network infrastructure, and managed IT services. With over 20 years of industry experience, Valeo Networks is headquartered in Rockledge, FL, with additional locations nationwide. Learn more at www.valeonetworks.com. A-1 is an established and fast-growing disaster-response company which provides on-demand resources, services, and logistics during catastrophes. Services include large-loss restoration services, commercial construction, staffing, restoration equipment rental & monitoring, as well as time and material documenting and preparation during natural disasters such as hurricanes, tornadoes, and freezing and flooding events that cause property damage. Headquartered in Charlotte, North Carolina, A-1’s extensive experience and seasoned personnel have allowed it to create a first-of-its-kind national network and partnership program that brings together service providers, supplies, equipment, and labor. Learn more at www.a1disasterresources.com. About the Fund SponsorClear Vision’s sponsor is an affiliate of Siebert Williams Shank, a leading non-bank financial services firm serving clients across industries and asset classes. It is both a minority-owned and women-owned enterprise. SWS Capital Management, an investment adviser affiliated with Siebert Williams Shank, serves as Clear Vision’s investment manager.To learn more about Clear Vision’s closings or investment portfolio, please visit www.clearvisionimpact.com. This press release (“Press Release”) is being published for informational purposes only regarding Clear Vision Impact Fund (“Clear Vision” or “CVIF”). One should not assume an investment in any of the described companies was or will be profitable. The companies listed in this Press Release do not represent all CVIF’s investments. All opinions, estimates and forecasts are based on information as of the date of this Press Release and are subject to change. Certain information contained in this Press Release constitutes “forward-looking statements,” which can be identified by the use of forward-looking terminology such as “may,” “will,” “should,” “expect,” “anticipate,” “target,” “project,” “estimate,” “intend,” “continue” or “believe,” or the negatives thereof or other variations thereon or comparable terminology. Due to various risks and uncertainties, actual events or results may differ materially from those reflected or contemplated in such forward-looking statements. CVIF has not vetted the companies’ websites and CVIF’s provision of the companies’ website links should not be considered an endorsement of the information presented there. Contact Details Tom Butler +1 646-213-1802 TButler@ButlerPR.com Christian Agredo +1 646-213-0286 CAgredo@ButlerPR.com Company Website https://www.clearvisionimpact.com/

February 22, 2023 09:30 AM Eastern Standard Time

News Release

Predictive Oncology appoints Pamela Bush as new chief business officer

Predictive Oncology Inc.

Predictive Oncology's new chief business officer Pamela Bush joined Proactive's Natalie Stoberman to share her plans for her new role with the company. Bush will lead all business development, partnering and growth strategies for Predictive Oncology and spearhead the company’s strategic, operational and financial planning initiatives for both existing customers and emerging new markets. The new CBO previously served as senior vice president of strategic sales and business development at the company. In that role, she was instrumental in guiding Predictive Oncology's strategic direction, expanding its product offerings and launching commercialization efforts for its flagship technology platform. Contact Details Proactive US +1 347-449-0879 na-editorial@proactiveinvestors.com

February 21, 2023 02:04 PM Eastern Standard Time

Video

News Release

ChitogenX partners with Polytechnique Montréal on federal grant for ORTHO-R regenerative treatment

ChitogenX Inc

ChitogenX CEO Phil Deschamps joined Proactive's Natalie Stoberman with news of the company's latest federal grant and partnership deal with Polytechnique Montréal to expand the ORTHO- R platform in regenerative medicine. Deschamps said the company has obtained a $3,472,000 grant from The Natural Sciences and Engineering Research Council of Canada (NSERC) and Prima Québec and will collaborate with Polytechnique Montréal throughout the four-year grant period to advance the scientific development, expand the scope of indications, develop new biomaterials for regenerative medicine and accelerate the commercial readiness of its flagship ORTHO-R technology platform. Contact Details Proactive Canada +1 604-688-8158 na-editorial@proactiveinvestors.com

February 21, 2023 01:53 PM Eastern Standard Time

Video

ZeaKal Elects Jay Brumfield as Chairman, Hank Plain as Board Member

ZeaKal

ZeaKal, today announced the appointment of Jay Brumfield as its Board of Directors Chairman and Hank Plain as Board Member. The appointments further validate the market potential of ZeaKal's novel PhotoSeed® trait technology and the broad impact of its ‘NewType’ business model to transform agriculture. “As one of ZeaKal’s initial investors, I have witnessed the remarkable evolution of the company’s vision to improve the photosynthetic capacity of plants”, said Brumfield. “As Chairman, I am honored for the opportunity to further advance the company’s mission to convert carbon dioxide into improved productivity and nutritional quality across the world’s most important crops.” As an accomplished entrepreneur and investor in healthcare and agriculture, Brumfield’s expertise will help ZeaKal expand its strategic partnerships and commercial opportunities globally. Brumfield’s background includes being president and CEO of two healthcare start-ups that were sold to publicly held strategics and then co-founder and managing director of Finistere Ventures. While at Finistere, he led its investment in ZeaKal as well as six others that were successfully exited, including ag tech start-up Athenix. Board of Directors Bolster Governance Profile Ahead of 2024 Commercialization As a new board member, Plain brings additional expertise having been involved in some of the largest venture-backed life science exits over the last decade. Currently, he is a special partner of Lightstone Ventures and a general partner at Morgenthaler Ventures. “Having grown up in central Illinois, I clearly see how ZeaKal’s technology and vision will restore profitability and resilience to U.S. agriculture, starting with delivering more value to the grower,” said Plain. “As a science innovation company, ZeaKal’s proprietary technology, innovative business model and impact on the future of agriculture aligns with my commitment to tackle global challenges like climate change and access to affordable nutrition.” In addition to ZeaKal, Plain serves on the boards of Imperative Care, Nuvaira, Moximed and Setpoint. “ZeaKal’s PhotoSeed technology and NewType model will deliver more equitable value to our supply chain partners as we improve profitability for all participants,” said Han Chen, co-founder and CEO of ZeaKal. “Together with our management team and partners, I’m excited to fully engage Jay and Hank as we accelerate our growth across several crop areas and usher in a new dawn of plant trait technologies.” Over the past two years, ZeaKal built a fully integrated supply chain, with Gro Alliance and Perdue AgriBusiness as its first partners, to deliver better, more sustainable food starting with seed genetics that is more equitable for farmers. In 2022, U.S. Department of Agriculture’s Animal and Plant Health Inspection Service (APHIS) deregulated ZeaKal’s seed technology for soybeans paving the way for broad adoption across the U.S. market. About ZeaKal: At ZeaKal, we are building a value driven “NewType” of agriculture to harmonize the needs of farmers, consumers, and our planet. Our flagship plant trait technology, PhotoSeed™, helps crops capture more carbon and sunlight, leading to healthier, nutrient-rich food and feed grown on a smaller environmental footprint. We go beyond science to make affordable nutrition more sustainable, with marketable differentiation for growers. Discover how we are transforming carbon to nutrition: zeakal.com or @zeakal on Twitter. Contact Details AgTech PR for ZeaKal Jennifer Goldston +1 816-260-0040 jennifer@agtechpr.com Company Website https://www.zeakal.com

February 21, 2023 08:00 AM Central Standard Time

Image

AliMed, Inc. Welcomes Fortune 100 Healthcare Leader And Former AORN Foundation Board Member to Its Sales Leadership Team

AliMed, Inc.

AliMed, Inc., a Massachusetts-based medical supply manufacturer and distributor, announced today the naming of Gregg Brewster as Vice President of Global Commercial Partnerships, joining the company’s growing sales leadership team. In this newly created role, Brewster will lead AliMed’s channel growth strategies with distributor partners and group purchasing organizations (GPOs), focusing on key accounts and regional GPOs to foster and strengthen relationships aimed at expanding AliMed’s footprint in the post-acute care space. A 39-year healthcare industry veteran with sales leadership roles at Owens & Minor and Cardinal Health, Brewster has spent much of his career driving all aspects of sales, marketing, and financial performance while building strategic partnerships with top-tier integrated delivery networks (IDNs) and national GPOs. Most recently, Brewster worked as an independent consultant, supporting hospitals and large regional purchasing coalitions to improve supply chain efficiencies, allowing them to focus on reducing costs, expanding diversity business initiatives, and improving patient care. “Gregg brings an incredible amount of expertise and depth to this role,” said Adam Epstein, CEO of AliMed. “He’s built a tremendous reputation in the distribution sector, and his leadership mentoring style is legendary. No one is more uniquely qualified to not only navigate the complexities of these critical growth areas but bolster our position within them. We’re thrilled to welcome him to AliMed.” A “student of the industry,” Brewster has been recognized for his mentorship and training efforts with young professionals and has served as a representative on corporate and industry boards, championing community involvement, diversity, and women’s initiatives. He just completed a six-year membership on the Association of periOperative Registered Nurses (AORN) Foundation Board of Directors and was recently appointed by the governor of Arizona as a regent on his home state of Arizona’s Board of Regents. “Healthcare is a fast-paced industry, and it’s easy to get left behind in today’s landscape,” said Brewster. “I’m passionate about my mission to help arm our internal teams with the knowledge and tools required to fortify our sales approach while nurturing and inspiring performances to ensure AliMed is always at the front of the line.” Brewster holds a bachelor’s degree from Arizona State University and resides in Phoenix. About AliMed AliMed, Inc. manufactures and distributes acute and post-acute medical products and devices. For over 50 years, AliMed has innovated to deliver flexible supply chain solutions with superior service and products focused on safety and productivity for the continuum of care. AliMed’s broad portfolio of products for domestic and international care providers, dealers, and distributors are designed to improve patient outcomes and experiences from “hospital to home.” Contact Details Amy Fontaine, Marketing Communications +1 857-205-8264 afontaine@alimed.com Company Website https://www.alimed.com/

February 21, 2023 09:00 AM Eastern Standard Time

Image